Stille AB STIL

Updated: 11 Jun 2026

First North | Industrials | Surgical instruments and tables

No signal published yet

We already track Stille and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Stille free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
First North
Type
Industrials
Sector
Surgical instruments and tables
We're already tracking Stille AB — here are the latest events we've registered

Recent News

  • On April 24, 2026, Stille reported a 38.5 percent revenue growth for the first quarter, with net sales reaching 179.1 million SEK. The results were driven by strong demand and the successful integration of acquired businesses such as Fehling Instruments.

What Firelda Watch includes for Stille AB

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Stille AB will be delivered in the same format.

Want to follow Stille AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Stille free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Stille AB STIL
Stille — follow and we'll monitor it
Follow Stille free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.